Full metadata record

DC Field Value Language
dc.contributor.authorAhn, J. H.-
dc.contributor.authorKwak, J. A.-
dc.contributor.authorKim, J. I.-
dc.contributor.authorYou, J. R.-
dc.contributor.authorCho, E. Y.-
dc.contributor.authorKwon, E. A.-
dc.contributor.authorKeum, G. C.-
dc.contributor.authorNam, J. H.-
dc.contributor.authorYun, J. W.-
dc.contributor.authorKang, B. C.-
dc.date.accessioned2024-01-12T02:47:52Z-
dc.date.available2024-01-12T02:47:52Z-
dc.date.created2023-02-06-
dc.date.issued2022-12-01-
dc.identifier.issn1043-0342-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/76519-
dc.identifier.urihttps://www.liebertpub.com/doi/10.1089/hum.2022.29225.abstracts-
dc.description.abstractMessenger RNA (mRNA) vaccine has emerged as an attractive agent for prevention of infectious disease and anti-cancer therapy. However, there is a fatal risk that the safety evaluation for mRNA vaccine have not been fully studied yet. In this study, we evaluated the safety of four type of COVID-19 S-protein targeting mRNA vaccines with different compositions (C2/LNP90, C2LNP128, C3LNP90 and C3LNP128). Theses vaccines were intramuscularly injected to 6-wk old male and female ICR mice with twice at an interval of 2 wks. The necropsy was carried out on 2 days or 14 days after secondary injection. The results showed that the body weight was decreased for 2days after the first injection in C2/LNP128 and C3/LNP128-injected mice, but it was almost recovered at 7day post injection (dpi). At 2 dpi after secondary injection, the endpoint blood analysis of demonstrated that C2/LNP128 and C3/LNP128 decreased the number of lymphocytes, monocytes and reticulocytes carrying the abnormal level of liver function indicator such as albumin, AST, ALT and total protein. Additionally, C2/LNP128 decreased the number of platelet and C3LNP128 decreased the number of red blood cells, respectably. Spleen and inguinal lymph node were enlarged in all experimental group. Notably, C2/LNP128 and C3/LNP128 induced severe edema in injection site, femoris muscle. At 14 dpi after secondary injection, the toxicity that was observed at 2 dpi after secondary injection was recovered. These results suggest that the potential side effects of mRNA vaccines must be systematically evaluated with multiple aspect of toxicolog-
dc.languageEnglish-
dc.publisherMARY ANN LIEBERT, INC-
dc.titlePre-clinical safety evaluation for mRNA-vaccine development in mouse model-
dc.typeConference-
dc.identifier.doi10.1089/hum.2022.29225.abstracts-
dc.description.journalClass1-
dc.identifier.bibliographicCitation29th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy (ESCGT), pp.A197-
dc.citation.title29th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy (ESCGT)-
dc.citation.startPageA197-
dc.citation.endPageA197-
dc.citation.conferencePlaceUS-
dc.citation.conferencePlaceEdinburgh, SCOTLAND-
dc.citation.conferenceDate2022-10-11-
dc.relation.isPartOfHUMAN GENE THERAPY-
dc.identifier.wosid000899950600618-

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE